Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Meiji Kicks Off Japanese PI Study of Stelara Biosimilar
May 12, 2022
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
- Asahi Kasei Sues Sawai over Manufacturing Method of Teribone Generic
May 11, 2022
- Kyowa Kirin’s Q1 Sales Up 8.2% on Robust Overseas Performance Driven by Crysvita
May 11, 2022
- Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
- Healios, NCC to Evaluate Antitumor Effects of eNK Cells
May 11, 2022
- Santen Snags China OK for Vernal Keratoconjunctivitis Drug
May 11, 2022
- Eisai Completes Rolling Submission for Lecanemab in US
May 11, 2022
- Eisai Sets to File Ultra-High Dose Mecobalamin for ALS in Japan
May 11, 2022
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
- 1st Dose of COVID-19 Jab Given in Adult and Pediatric Trials: KM Biologics/Meiji
May 10, 2022
- Kyoto University’s BMS Building Breaks Ground for I/O Research with 5.5 Billion Yen Donation
May 10, 2022
- Argenx’s 1st Med in Japan Vyvgart Now Available for Generalized Myasthenia Gravis
May 10, 2022
- FDA Defers PDUFA Date for Myfembree for Endometriosis Use: Myovant/Pfizer
May 10, 2022
- Maruho Grabs Japan Rights for JAK2 Inhibitor Ruxolitinib Cream
May 9, 2022
- Sumitomo Pharma Grants Narcolepsy Drug Rights to Jazz
May 9, 2022
- Enhertu Gets Second-Line Breast Cancer Nod in US: Daiichi Sankyo/AZ
May 9, 2022
- Eisai Slashes FY2021 Profit Outlook on Aduhelm Woes
May 9, 2022
- BMS Begins New PI for Compound Derived from PeptiDream Platform
May 9, 2022
- Emgality Now Available for Self-Injection in Japan: Lilly/Daiichi Sankyo
May 9, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…